ERBB2 and cancer: In a systematic review and meta-analysis published in 2014, Elias et al. [46] reported that higher enhancement within the tumor is associated with the luminal B subtype, while HER2-enriched cancers are more likely to show fast initial enhancement or wash-out kinetics with circumscribed margins.